Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
benmelstobart + anlotinib + etoposide
- Development stage
- Phase 3
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Benmelstobart + anlotinib + etoposide is a combination therapeutic regimen primarily used as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). The regimen consists of **benmelstobart**, a humanized IgG1 monoclonal antibody that acts as a programmed death-ligand 1 (PD-L1) inhibitor; **anlotinib**, a multi-target small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR 1-3), fibroblast growth factor receptors (FGFR 1-4), platelet-derived growth factor receptors (PDGFR α/β), and c-Kit; and **etoposide**, a standard cytotoxic chemotherapy agent that inhibits DNA topoisomerase II. This triplet therapy was evaluated in the pivotal Phase 3 ETER701 trial, which demonstrated a significant improvement in both progression-free survival (PFS) and overall survival (OS) compared to standard chemotherapy. Benmelstobart was developed by Chia Tai Tianqing Pharmaceutical Group and received approval from China's NMPA in May 2024 for use in this combination for first-line SCLC.
- Other names
- benmelstobart combined with anlotinib and etoposide
02
Targets
TOP2A (DNA topoisomerase II)FGFR (FGFR family)CD274 (Programmed cell death protein 1 ligand 1)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on benmelstobart + anlotinib + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on benmelstobart + anlotinib + etoposide.